BIIB · Healthcare

BIOGEN INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-09

Acquisition / Partnership / DivestitureImportance 34 · Surprise 42
Biogen’s acquisition of Apellis contributed to revenue growth in the second quarter of 2026. The transaction expanded Biogen’s portfolio alongside newer therapies in neurology and rare diseases. The reported results…
Product / Drug Pipeline ProgressImportance 26 · Surprise 24
Biogen’s newer therapies contributed to higher second-quarter 2026 revenue, indicating increasing sales from products beyond its legacy portfolio. The company is transitioning toward a broader neurology and…
Revenue Performance and MixImportance 17 · Surprise 24
Biogen reported higher revenue in the second quarter of 2026, supported by newer therapies and the Apellis acquisition. Net income and diluted EPS declined materially despite the revenue increase. The results indicate…

Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
Biogen completed its acquisition of RayThera, Inc. on August 6, 2026, expanding its immunology portfolio with multiple small-molecule assets. The transaction carries total consideration of up to $1 billion, comprising…
Litigation and Legal RiskImportance 28 · Surprise 42
Biogen reached a preliminary settlement agreement with investors in a class-action lawsuit concerning disclosures about clinical trial data for its Alzheimer’s drug Aduhelm. The plaintiffs alleged that Biogen…

Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
Biogen completed its acquisition of RayThera, Inc. on August 6, 2026, expanding its immunology portfolio with multiple small-molecule assets. The transaction carries total consideration of up to $1 billion, comprising…
Product / Drug Pipeline ProgressImportance 37 · Surprise 42
Denali Therapeutics discontinued the Parkinson’s disease program BIIB122/DNL151 after its Phase 2b study failed to meet endpoints. BIIB122/DNL151 was being developed in collaboration with Biogen, making the…